Clinical trial NCT02199236: Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management
Official title: A Phase I, Dose Escalation Trial of Endoluminal High Dose Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Rectal or Anal Cancer
Keywords: High-Dose-Rate Brachytherapy
oral capecitabine
infusional 5-FU
Questionnaires
14-104
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2014-07-24
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see what amount of radiation is safe to give to rectal or anal cancer patients who are being treated with a procedure called brachytherapy.


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed locally residual or recurrent cancer of the rectum or anus
* Prior pelvic EBRT
* Age \> or = to 18 years
* ECOG performance status 0, 1, or 2
* At least 4 weeks from prior major surgery or radiotherapy
* Have undergone Surgical, Medical and Radiation Oncology evaluations to confirm :

  * Eligible for infusional 5-FU or capecitabine
  * Will not undergo surgery for the study disease
  * Able to receive HDR brachytherapy ANC ≥ 1.5 cells/mm3 and PLT ≥100,000/mm3
* Adequate Renal function: Creatinine \<1.5 x the upper limit of normal (ULN) or calculated creatinine clearance of ≥ 50cc/min
* Adequate Hepatic functions: Bilirubin less than 1.5 mg/dL; (except in patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
* AST or ALT \<3xULN, or \<5x ULN if known liver metastases
* Normal Cardiac function:

  * No active coronary artery disease;
  * No New York Heart Association class II, III or IV disease;
  * No arrhythmia requiring treatment
  * Maximum tumor length of 7 cm at time of brachytherapy treatment start

Exclusion Criteria:

* Women who are pregnant.
* Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire treatment period and after receipt of brachytherapy. Male subjects must also agree to use effective contraception during the treatment period and until 1 year after the completion of brachytherapy.
* Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study.
* Patients on concurrent anti-cancer therapy other than that allowed in the study.
* Contraindications to general anesthesia

Primary outcomes:
measure: maximum tolerated dose (MTD)
timeFrame: 1 year
Secondary outcomes:
measure: tumor response
timeFrame: 3, 6, and 12 months
Other outcomes:
Locations:
city: Basking Ridge
country: United States
facility: Memorial Sloan Kettering Basking Ridge (Follow Up Only)
state: New Jersey
city: Middletown
country: United States
facility: Memorial Sloan Kettering Monmouth (Follow Up Only)
state: New Jersey
city: Commack
country: United States
facility: Memorial Sloan Kettering Commack (Consent and Follow up)
state: New York
city: Harrison
country: United States
facility: Memorial Sloan Kettering Westchester (Follow Up Only)
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Rockville Centre
country: United States
facility: Memorial Sloan Kettering Rockville Center (Follow Up Only)
state: New York
city: Uniondale
country: United States
facility: Memorial Sloan Kettering Nassau (Follow-Up only)
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Abraham Wu, MD
role: PRINCIPAL_INVESTIGATOR
References: